You are here: Industry Insights > CanSinoBIO

News List

CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health ACN Newswire
June 20, 2025
CanSino Biologics Inc. has developed and launched its 13-valent pneumococcal conjugate vaccine, trade name "iPneucia?", optimized for China’s local pneumococcal epidemiology, aiming to provide more precise and safer protection for Chinese children.
CanSinoBIO Announces Approval for its MCV4 Product Menhycia? in China prnasia
January 10, 2022
CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China ("NMPA") granted approval for its ACYW135 Meningococcal Conjugate Vaccine...
Convidecia? Phase III Results Published in The Lancet prnasia
December 27, 2021
CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that The Lancet[1] published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine...
Aerogen and CanSinoBIO to partner for inhaled delivery of Covid-19 vaccine Pharmaceutical-Technology
December 13, 2021
CanSinoBIO has signed a development and commercial supply collaboration with Ireland based company Aerogen for the inhaled recombinant Covid-19 vaccine, Convidecia.
Early data shows CanSinoBIO’s inhaled COVID-19 vaccine triggers immune response pharmatimes
July 29, 2021
CanSinoBIO’s inhaled COVID-19 vaccine candidate was found to trigger immune responses with no serious side effects reported, according to an early-stage clinical study.
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia? in Chile prnasia
April 09, 2021
CanSino Biologics Inc. announced that the Instituto de Salud Pública de Chile ("ISP") granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia?).
Pakistan to conduct phase-III clinical trial of COVID-19 vaccine from CanSinoBio expresspharma
August 19, 2020
The NIH said this would be the first-ever phase-III clinical trial for any vaccine in Pakistan.
First COVID-19 vaccine given green light for Phase I trial in China europeanpharmaceuticalreview
July 02, 2020
CanSino Biologics’ Ad5-nCoV vaccine, a potential COVID-19 prophylactic, has been approved for study in a Phase I clinical trial in China.
Sartorius Supports the Development of the First Vaccine Candidate Against the Novel Coronavirus to Enter Clinical Trials .b3cnewswire
March 25, 2020
CanSinoBIO and the Institute of Bioengineering used Sartorius’ BIOSTAT? STR single-use bioreactor system for the upstream preparation of the recombinant vaccine, thus ensuring the rapid linear amplification of the adenovirus vector (Ad5-nCoV) and ultimate